Letrozol Pentafarma (Letrozole)

Letrozole works by reversibly inhibiting the aromatase enzyme, which is responsible for converting androgens into estrogens in peripheral tissues. By lowering circulating estrogen levels, it deprives estrogen‑dependent breast cancer cells of a key growth stimulus, thereby slowing disease progression.

The prescribed dose of letrozole is determined by the treating physician based on the individual patient's clinical situation. In adult practice, a common regimen is 2.5 mg taken once daily, but the exact dosing schedule must follow the prescriber’s order and any local guidelines.

Letrozole is contraindicated during pregnancy and is not recommended for breastfeeding mothers. The drug can cause fetal harm by disrupting normal estrogen pathways, and it may be excreted in breast milk, posing a risk to the infant. Women of child‑bearing potential should use effective contraception while on therapy.

To order Letrozol Pentafarma, visit the product page on gnhindia.com and submit an enquiry with the required quantity and your institutional credentials. GNH India will respond with a quotation, confirm availability, arrange shipping (including any required cold‑chain handling), and provide the necessary import documentation for hospitals, pharmacies, or procurement teams.

Letrozole is a third‑generation aromatase inhibitor with a longer half‑life and higher potency than earlier agents such as anastrozole. Clinical studies show comparable efficacy in controlling hormone‑dependent breast cancer, while side‑effect profiles may differ; for example, letrozole is more frequently associated with bone‑density loss, whereas anastrozole may cause fewer joint symptoms.

Letrozol Pentafarma should be stored at ambient temperature below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and store out of reach of children. Do not refrigerate or freeze the product.

Letrozol Pentafarma is taken orally, usually as a whole tablet swallowed with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and consistency to maintain stable blood levels.

Serious risks associated with letrozole include severe bone loss leading to fractures, hepatic dysfunction such as elevated liver enzymes or hepatitis, thromboembolic events like deep‑vein thrombosis or pulmonary embolism, and rare but severe allergic reactions (anaphylaxis). Patients should be monitored regularly for these complications.

Letrozole should not be used in premenopausal women, pregnant or nursing patients, individuals with known hypersensitivity to letrozole or its excipients, and patients with uncontrolled severe liver disease. Use in these populations may be ineffective or pose significant safety concerns.